This article was put together by NORML and appears here with permission.
Researchers worldwide published a record 4,300+ scientific papers on the subject of cannabis, according to the results of a keyword search of the National Library of Medicine/PubMed.gov website.
This exceeds the total number of papers published during all of last year, when scientists published over 4,200 papers. At the time, that total was the highest number of cannabis-specific papers ever published in a single year.
Since 2010, scientists have published over 30,000 peer-reviewed papers specific to cannabis, with the annual number of total papers increasing every year. By comparison, researchers published fewer than 3,000 total papers about marijuana in the years between 1990 and 1999 and fewer than 2,000 total studies during the 1980s.
“Despite claims by some that marijuana has yet to be subject to adequate scientific scrutiny, scientists’ interest in studying cannabis has increased exponentially in recent years, as has our understanding of the plant, its active constituents, their mechanisms of action, and their effects on both the user and upon society,” NORML’s deputy director Paul Armentano said. “It is time for politicians and others to stop assessing cannabis through the lens of ‘what we don’t know’ and instead start engaging in evidence-based discussions about marijuana and marijuana reform policies that are indicative of all that we do know.”
Much of this uptick in scientific interest surrounding cannabis is a result of researchers’ newfound focus on marijuana’s therapeutic activities. A 2018 paper assessing trends in cannabis-related publications concluded that the total number of peer-reviewed publications dedicated to medical cannabis has increased nine-fold since the year 2000.
In all, PubMed.gov now cites over 42,500 scientific papers on marijuana. Available to the public online since 1996, PubMed is a free resource supporting the search and retrieval of biomedical and life sciences literature.
Summaries of over 450 studies assessing the safety and therapeutic efficacy of cannabis and cannabinoids in different patient populations is available online from NORML.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.